Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia

References

• SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin201565152925559415
   PubMed Web of Science ®Google Scholar
• SEER Cancer Statistics Review [webpage on the Internet]Previous Version: SEER Cancer Statistics Review, 1975–20102015 Available from: http://seer.cancer.gov/archive/csr/1975_2010/Accessed October 4, 2015
   Google Scholar
• HungerSPLuXDevidasMImproved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology groupJ Clin Oncol201230141663166922412151
   PubMed Web of Science ®Google Scholar
• StockWJohnsonJLStoneRMDose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Cancer20131191909822744771
   PubMed Web of Science ®Google Scholar
• ThomasDAO’BrienSFaderlSChemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemiaJ Clin Oncol201028243880388920660823
   PubMed Web of Science ®Google Scholar
• StillerCAChessellsJMFitchettMNeurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG studyBr J Cancer19947059699727947106
   PubMed Web of Science ®Google Scholar
• StrevensMJLilleymanJSWilliamsRBShwachman’s syndrome and acute lymphoblastic leukaemiaBr Med J19782612918277273
   PubMedGoogle Scholar
• PassargeEBloom’s syndrome: the German experienceAnn Genet1991343–41791971809225
   PubMedGoogle Scholar
• TaylorAMMetcalfeJAThickJMakYFLeukemia and lymphoma in ataxia telangiectasiaBlood19968724234388555463
   PubMed Web of Science ®Google Scholar
• De JongeRTissingWJEHooijbergJHPolymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemiaBlood2009113102284228919020309
   PubMed Web of Science ®Google Scholar
• PrestonDLKusumiSTomonagaMCancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950–1987Radiat Res19941372 supplS68S978127953
   PubMed Web of Science ®Google Scholar
• ErratumRadiat Res19941391129
   Google Scholar
• GreavesMInfection, immune responses and the aetiology of childhood leukaemiaNat Rev Cancer20066319320316467884
   PubMed Web of Science ®Google Scholar
• CampoESwerdlowSHHarrisNLPileriSSteinHJaffeESThe 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applicationsBlood2011117195019503221300984
   PubMed Web of Science ®Google Scholar
• HoelzerDThielELöfflerHPrognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adultsBlood19887111231313422030
   PubMed Web of Science ®Google Scholar
• WetzlerMDodgeRKMrózekKProspective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experienceBlood199993113983399310339508
   PubMed Web of Science ®Google Scholar
• HoelzerDPersonalized medicine in adult acute lymphoblastic leukemiaHaematologica2015100785585826130512
   PubMed Web of Science ®Google Scholar
• CampanaDMinimal residual disease in acute lymphoblastic leukemiaHematol Hematology Am Soc Hematol Educ Program2010201071221239764
   PubMed Web of Science ®Google Scholar
• BassanRSpinelliOOldaniEImproved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)Blood2009113184153416219141862
   PubMed Web of Science ®Google Scholar
• LarsonRADodgeRKBurnsCPA five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811Blood1995858202520377718875
   PubMed Web of Science ®Google Scholar
• LinkerCALevittLJO’DonnellMFormanSJRiesCATreatment of adult acute lymphoblastic leukemia with intensive cyclical chemo-therapy: a follow-up reportBlood19917811281428221835410
   PubMed Web of Science ®Google Scholar
• KantarjianHThomasDO’BrienSLong-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemiaCancer2004101122788280115481055
   PubMed Web of Science ®Google Scholar
• SiveJIBuckGFieldingAOutcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trialBr J Haematol2012157446347122409379
   PubMed Web of Science ®Google Scholar
• HuguetFLeguayTRaffouxEPediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 studyJ Clin Oncol200927691191819124805
   PubMed Web of Science ®Google Scholar
• BleyerWAPoplackDGProphylaxis and treatment of leukemia in the central nervous system and other sanctuariesSemin Oncol19851221311483892694
   PubMed Web of Science ®Google Scholar
• CortesJO’BrienSMPierceSKeatingMJFreireichEJKantarjianHMThe value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemiaBlood1995866209120977662956
   PubMed Web of Science ®Google Scholar
• GökbugetNKnebaMRaffTGerman Multicenter Study Group for Adult Acute Lymphoblastic LeukemiaAdult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapiesBlood201212091868187622442346
   PubMed Web of Science ®Google Scholar
• LitzowMRFinally moving forward in adult ALLBlood2015125162453245425883226
   PubMed Web of Science ®Google Scholar
• GuptaVRichardsSRoweJAcute Leukemia Stem Cell Transplantation Trialists’ Collaborative Group. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysisBlood2013121233935023165481
   PubMed Web of Science ®Google Scholar
• FieldingAKRichardsSMChopraRMedical Research Council of the United Kingdom Adult ALL Working PartyEastern Cooperative Oncology GroupOutcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 studyBlood2007109394495017032921
   PubMed Web of Science ®Google Scholar
• GökbugetNStanzeDBeckJGerman Multicenter Study Group for Adult Acute Lymphoblastic LeukemiaOutcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantationBlood20121202032204122493293
   PubMed Web of Science ®Google Scholar
• TavernierEBoironJMHuguetFGET-LALA GroupSwiss Group for Clinical Cancer Research SAKKAustralasian Leukaemia and Lymphoma GroupOutcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trialLeukemia2007211907191417611565
   PubMed Web of Science ®Google Scholar
• KantarjianHGandhiVCortesJPhase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemiaBlood200310272379238612791647
   PubMed Web of Science ®Google Scholar
• AbbiKKSRybkaWEhmannWCClaxtonDFPhase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemiaClin Lymphoma Myeloma Leuk2015151414625085441
   PubMed Web of Science ®Google Scholar
• Le JeuneCThomasXAntibody-based therapies in B-cell lineage acute lymphoblastic leukaemiaEur J Haematol2015949910824981395
   PubMed Web of Science ®Google Scholar
• GruppSAKalosMBarrettDChimeric antigen receptor-modified T cells for acute lymphoid leukemiaN Engl J Med2013368161509151823527958
   PubMed Web of Science ®Google Scholar
• KantarjianHThomasDWayneASO’BrienSMonoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemiaJ Clin Oncol201230313876388322891271
   PubMed Web of Science ®Google Scholar
• AiJAdvaniACurrent status of antibody therapy in ALLBr J Haematol2015168447148025382151
   PubMed Web of Science ®Google Scholar
• RaponiSDe ProprisMSIntoppaSFlow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 casesLeuk Lymphoma20115261098110721348573
   PubMed Web of Science ®Google Scholar
• FujimotoMPoeJCInaokiMTedderTFCD19 regulates B lymphocyte responses to transmembrane signalsSemin Immunol19981042672779695183
   PubMed Web of Science ®Google Scholar
• BarachoGVMileticAVOmoriSACatoMHRickertRCEmergence of the PI3-kinase pathway as a central modulator of normal and aberrant B cell differentiationCurr Opin Immunol201123217818321277760
   PubMed Web of Science ®Google Scholar
• DreierTLorenczewskiGBrandlCExtremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibodyInt J Cancer2002100669069712209608
   PubMed Web of Science ®Google Scholar
• NagorsenDKuferPBaeuerlePABargouRBlinatumomab: a historical perspectivePharmacol Ther2012136333434222940266
   PubMed Web of Science ®Google Scholar
• NagorsenDBaeuerlePAImmunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomabExp Cell Res201131791255126021419116
   PubMed Web of Science ®Google Scholar
• OffnerSHofmeisterRRomaniukAKuferPBaeuerlePAInduction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cellsMol Immunol200643676377116360021
   PubMed Web of Science ®Google Scholar
• Blincyto® (blinatumomab) Available from: http://pi.amgen.com/united_states/blincyto/blincyto_pi_hcp_english.pdfAccessed October 11, 2015
   Google Scholar
• WuBHijaziYWolfABrandlCSunYNZhuMPharmacokinetics (PK) of blinatumomab and its clinical implicationsJ Clin Oncol20133115 abstract 3048
   Web of Science ®Google Scholar
• KaplanJBGrischenkoMGilesFJBlinatumomab for the treatment of acute lymphoblastic leukemiaInvest New Drugs20153361271127926383529
   PubMed Web of Science ®Google Scholar
• BargouRLeoEZugmaierGTumor regression in cancer patients by very low doses of a T cell-engaging antibodyScience2008321589197497718703743
   PubMed Web of Science ®Google Scholar
• KlingerMBrandlCZugmaierGImmunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomabBlood2012119266226623322592608
   PubMed Web of Science ®Google Scholar
• ToppMSKuferPGökbugetNTargeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survivalJ Clin Oncol201129182493249821576633
   PubMed Web of Science ®Google Scholar
• ToppMSGökbugetNZugmaierGLong-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLBlood2012120265185518723024237
   PubMed Web of Science ®Google Scholar
• GökbugetNDombretHBonifacioMBLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL)Poster presented at: American Society of Hematology (ASH) Annual MeetingDecember 6–9, 2014San Franscisco, CA Abstract 379
   Google Scholar
• ToppMSGökbugetNZugmaierGPhase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemiaJ Clin Oncol201432364134414025385737
   PubMed Web of Science ®Google Scholar
• ToppMSGökbugetNSteinASSafety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyLancet Oncol2015161576625524800
   PubMed Web of Science ®Google Scholar
• SchlegelPLangPZugmaierGPediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomabHaematologica20149971212121924727818
   PubMed Web of Science ®Google Scholar
• RiberaJ-MFerrerARiberaJGenescàEProfile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemiaOnco Targets Ther201581567157426170691
   PubMed Web of Science ®Google Scholar
• BarrettDMTeacheyDTGruppSAToxicity management for patients receiving novel T-cell engaging therapiesCurr Opin Pediatr2014261434924362408
   PubMed Web of Science ®Google Scholar
• TeacheyDTRheingoldSRMaudeSLCytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapyBlood2013121265154515723678006
   PubMed Web of Science ®Google Scholar
• MartinelliGDombretHChevallierPComplete molecular and hematologic response in adult patients with relapsed/refractory (R/R) Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia (ALL) following treatment with blinatumomab: results from a phase 2 single-arm, multicenter study (ALCANTARA)Blood2015126issue 23 abstract 679
   PubMed Web of Science ®Google Scholar
• MaudeSLFreyNShawPAChimeric antigen receptor T cells for sustained remissions in leukemiaN Engl J Med2014371161507151725317870
   PubMed Web of Science ®Google Scholar